Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Key Points

Biotech stocks have a reputation for being high risk, high reward.
Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
5 stocks we like better than Denali Therapeutics

Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Should you invest $1,000 in Denali Therapeutics right now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Companies Mentioned in This Article

Company	MarketRank™	Current Price	Price Change	Dividend Yield	P/E Ratio	Consensus Rating	Consensus Price Target
Denali Therapeutics (DNLI)	3.669 of 5 stars	$17.84	-2.3%	N/A	-16.52	Buy	$41.22
Ultragenyx Pharmaceutical (RARE)	4.3496 of 5 stars	$42.87	-8.8%	N/A	-5.15	Moderate Buy	$91.55
Sarepta Therapeutics (SRPT)	4.8864 of 5 stars	$118.31	-3.7%	N/A	-19.33	Moderate Buy	$158.38
Pfizer (PFE)	4.9913 of 5 stars	$25.90	+0.2%	6.49%	71.94	Hold	$36.88
Exelixis (EXEL)	4.9825 of 5 stars	$22.70	-0.5%	N/A	35.47	Moderate Buy	$26.29
Moderna (MRNA)	4.0097 of 5 stars	$103.86	-1.2%	N/A	-8.37	Hold	$126.49
United Therapeutics (UTHR)	4.4056 of 5 stars	$235.08	+1.1%	N/A	11.85	Moderate Buy	$292.67
Biogen (BIIB)	4.9587 of 5 stars	$196.80	-0.7%	N/A	24.66	Moderate Buy	$298.96
Sanofi (SNY)	3.2653 of 5 stars	$46.24	+0.7%	2.98%	19.59	Hold	$55.00
Eli Lilly and Company (LLY)	4.8411 of 5 stars	$751.20	-0.1%	0.69%	129.52	Moderate Buy	$728.05